{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:19:46Z","timestamp":1761394786233},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/aog.0b013e31827c59f7","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T00:52:12Z","timestamp":1457139132000},"page":"321-329","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Significance of Serum Anti-Human Papillomavirus 16 and 18 Antibodies in Cervical Neoplasia"],"prefix":"10.1097","volume":"121","author":[{"given":"Doo Byung","family":"Chay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanbyoul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Suk","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunseop","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20210126","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":". Epidemiologic classification of human papillomavirus types associated with cervical cancer.","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-17-20210126","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ypmed.2011.08.017","article-title":"Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies.","volume":"53","author":"Tota","year":"2011","journal-title":"Prev Med"},{"key":"R3-17-20210126","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/path.1866","article-title":"HPV-mediated cervical carcinogenesis: concepts and clinical implications.","volume":"208","author":"Snijders","year":"2006","journal-title":"J Pathol"},{"key":"R5-17-20210126","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1155\/2007\/914823","article-title":"The epidemiology of human papillomavirus infection and cervical cancer.","volume":"23","author":"Bosch","year":"2007","journal-title":"Dis Markers"},{"key":"R6-17-20210126","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/jnci\/djq562","article-title":"Human papillomavirus testing in the prevention of cervical cancer.","volume":"103","author":"Schiffman","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R7-17-20210126","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/jnci\/djn444","article-title":". Efficacy of HPV DNA testing with cytology triage andor repeat HPV DNA testing in primary cervical cancer screening.","volume":"101","author":"Naucler","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R8-17-20210126","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1055-9965.EPI-03-0191","article-title":"Natural history of human papillomavirus type 16 virus-like particle antibodies in young women.","volume":"13","author":"Ho","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R9-17-20210126","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/AOG.0b013e3181edbeba","article-title":". Prevalence and seroprevalence of high-risk human papillomavirus infection.","volume":"116","author":"Kim","year":"2010","journal-title":"Obstet Gynecol"},{"key":"R10-17-20210126","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.ygyno.2010.01.024","article-title":"Pathology and epidemiology of HPV infection in females.","volume":"117","author":"Stanley","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R11-17-20210126","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1086\/604729","article-title":"Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004.","volume":"200","author":"Markowitz","year":"2009","journal-title":"J Infect Dis"},{"key":"R12-17-20210126","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/OLQ.0b013e31820bc880","article-title":". Prevalence of human papillomavirus antibodies in males and females in England.","volume":"38","author":"Desai","year":"2011","journal-title":"Sex Transm Dis"},{"key":"R13-17-20210126","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12272-009-1311-1","article-title":"Serologic response to human papillomavirus type 16 virus-like particles in Korean women with cervical precancerous and cancerous lesions.","volume":"32","author":"Jeong","year":"2009","journal-title":"Arch Pharm Res"},{"key":"R14-17-20210126","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri1260","article-title":"Prevention of cervical cancer through papillomavirus vaccination.","volume":"4","author":"Frazer","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"R15-17-20210126","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1128\/CDLI.12.8.959-969.2005","article-title":". Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.","volume":"12","author":"Dias","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"R16-17-20210126","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/sim.4780010106","article-title":"Mantel-Haenszel statistics and direct standardization.","volume":"1","author":"Woolson","year":"1982","journal-title":"Stat Med"},{"key":"R17-17-20210126","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1016\/j.vaccine.2011.07.007","article-title":"The first international standard for antibodies to HPV 16.","volume":"29","author":"Ferguson","year":"2011","journal-title":"Vaccine"},{"key":"R18-17-20210126","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrc700","article-title":"Immune evasion in human papillomavirus-associated cervical cancer.","volume":"2","author":"Tindle","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R19-17-20210126","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1473-3099(09)70108-2","article-title":". Clinicians guide to human papillomavirus immunology: knowns and unknowns.","volume":"9","author":"Einstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"R20-17-20210126","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/00016340701714703","article-title":". Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics.","volume":"87","author":"Skjeldestad","year":"2008","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R21-17-20210126","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PGP.0b013e3181f38dfe","article-title":". Prevalence of human papillomavirus infection and associated risk factors in young women in Brazil, Canada, and the United States: a multicenter cross-sectional study.","volume":"30","author":"Roteli-Martins","year":"2011","journal-title":"Int J Gynecol Pathol"},{"key":"R22-17-20210126","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1525-1438.2007.00844.x","article-title":"Human papillomavirus prevalence and predictors for cervical cancer among high-risk women from Rio de Janeiro, Brazil.","volume":"17","author":"Pereira","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"R23-17-20210126","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1054\/bjoc.2001.1779","article-title":". HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica.","volume":"84","author":"Hildesheim","year":"2001","journal-title":"Br J Cancer"},{"key":"R24-17-20210126","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer.","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"R25-17-20210126","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.","volume":"88","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"key":"R26-17-20210126","first-page":"4921","article-title":"Prognostic significance of serum antibodies to HPV-16 L1 virus-like particles in patients with invasive cervical cancer.","volume":"26","author":"Skiba","year":"2006","journal-title":"Anticancer Res"},{"key":"R27-17-20210126","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1067\/mob.2002.121898","article-title":". Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer.","volume":"186","author":"Heim","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"R28-17-20210126","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000141498","article-title":"Cervical cancer: screening and therapeutic perspectives.","volume":"17","author":"Sankaranarayanan","year":"2008","journal-title":"Med Princ Pract"},{"issue":"suppl 10","key":"R29-17-20210126","doi-asserted-by":"crossref","first-page":"K29","DOI":"10.1016\/j.vaccine.2008.06.019","article-title":". Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.","volume":"26","author":"Cuzick","year":"2008","journal-title":"Vaccine"},{"key":"R30-17-20210126","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0197-2456(00)00104-5","article-title":"Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates.","volume":"21","author":"Hsieh","year":"2000","journal-title":"Control Clin Trials"}],"container-title":["Obstetrics & Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0b013e31827c59f7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:53:02Z","timestamp":1620946382000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201302000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0b013e31827c59f7","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}